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Corticosteroids are a central part of many cancer treatment regimens. Neuropsychiatric 
toxicity has complicated their use, including an association with a spectrum of symptoms, 
from insomnia, cognitive impairment, mood symptoms to severe mental disorders, including 
mania, psychosis and severe depression. Although steroid-induced mental disorders were first 
reported in medicine more than 60 years ago, there is a dearth of evidence available to date 
on optimal treatment and prevention to guide cancer clinicians. We completed a systematic 
review of the current evidence for therapeutic and prophylactic intervention of steroid-
induced mental disorders in cancer. We searched Medline, Embase, and PsycINFO and 
selected studies related to steroid-induced mental disorder. The studies found were limited to 
case series and case reports only. 
Structured Abstract 
Corticosteroids are a central part of many cancer treatment regimens. Although steroid-
induced mental disorders were first reported in medicine more than 60 years ago, there is a 
dearth of evidence available to date on optimal treatment and prevention to guide cancer 
clinicians. Aim: We completed a systematic review of the evidence for therapeutic and 
prophylactic interventions of steroid-induced mental disorders in cancer patients. Methods: 
We searched Medline, Embase, and PsycINFO and selected studies related to steroid-induced 
mental disorders. Results: We retrieved nineteen articles from 4025 potential articles which 
mainly consisted of case reports. Conclusions: We emphasise the limited evidence available 
to date and reinforce the need for well-controlled trials to guide oncology clinicians in the 
treatment of steroid-induced mental disorders. 
Keywords: steroid-induced mental disorder, neuropsychiatric adverse effects, psychiatric 




Systemic corticosteroids are commonly prescribed for a broad range of medical conditions 
including immune/inflammatory disease (eg systemic lupus erythematosus (SLE) and the 
vasculitides), allergic conditions (eg asthma, hypersensitivity reactions, dermatitis) as well as 
different types of cancer. Corticosteroids are central to many cancer treatment regimens. 
They are used specifically in cancer to reduce inflammation, reduce tumour size, stimulate 
appetite, treat pain and emesis, and to prevent hypersensitivity reactions to chemotherapy [1].  
 
Physical side-effects associated with corticosteroid treatment are also broad, and include 
endocrine and metabolic disturbances, fluid and electrolyte imbalances, musculoskeletal and 
dermatological problems and immunosuppression [2]. Systemic corticosteroids penetrate the 
brain and corticosteroid receptors are present in abundance in the limbic system providing a 
potential mechanism for neuropsychiatric effects [3].The spectrum of neuropsychiatric 
adverse effects attributed to systemic corticosteroids is wide-ranging and includes symptoms 
of anxiety, depressed mood, sleep disturbance, suicidal ideation, impaired memory and 
concentration as well as mental disorders including mania, psychosis, severe depression and 
delirium [4-8]. The Diagnostic and statistical manual of mental disorders, 5
th
 Edition (DSM-
V) lists a number of criteria for medication-induced bipolar and related disorders including 
significant distress and impairment in functioning [9].  
 
Corticosteroid treatment therefore constitutes a ‘double-edged sword’, as one study put it, 
providing effective symptom relief but also problematic side-effects [8]. In cancer, 
neuropsychiatric effects of steroids may compromise treatment adherence and co-morbid 
mental disorder in cancer has a negative impact on outcome [10, 11]. 
 
When cortisone was first marketed commercially in 1950 [4], a number of troubling 
psychiatric side-effects were observed ranging in severity from insomnia and hypomania to 
psychosis and cognitive impairment [12-14].  Although the pathogenesis of these 
neuropsychiatric effects was poorly understood, early reports and investigations into the 
matter suggest that they occurred independently of a previous psychiatric history [15, 16] and 
that women were more likely to experience such side-effects [17, 18].  
 
From 1966, by using standardised in-hospital monitoring, the Boston Collaborative Drug 
Surveillance Program began to quantify on a large scale the adverse effects of prescription 
drugs including steroids. This program was the first to report a dose-response correlation 
between exogenous corticosteroids and likelihood of psychiatric adverse effects among 
general hospital inpatients [19]. In that study of 676 general hospital inpatients, the rate of 
‘severe psychiatric disturbance’ in those exposed to >80mg prednisone per day was 18.4%, 
compared with 4.6% of those receiving 40-80mg per day and 1.3% of those receiving less 
than 40mg per day.   
 
Early published case series supported the Boston program findings with a 5.7% average 
incidence of psychiatric symptoms secondary to corticosteroid treatment [20, 21] and more 
recent epidemiological research supports the association between higher dose of steroid and 
risk of severe neuropsychiatric outcomes [22]. Other than the prescribed dose of 
corticosteroid, no other risk factors for steroid-induced neuropsychiatric symptoms apart 
from past psychiatric history, have emerged [22, 23]. While smaller early studies did not 
support past psychiatric history as a risk factor for steroid-induced mental disorder [7, 15, 
16], more recent large-scale epidemiologic research does [22]. 
 
The clinical features of steroid side-effects have been better delineated through published 
case reports and case series.  Symptoms such as mood or cognitive changes typically appear 
within three to five days of beginning steroid treatment but can also manifest during 
withdrawal or indeed following complete cessation of treatment [24]. Various biological 
mechanisms have been suggested as responsible for the observed affective and cognitive 
changes following systemic steroids including: an imbalance of mineralocorticoid and 
glucocorticoid receptors in the brain; effects of steroids on dopaminergic and cholinergic 
pathways and pathological effects of steroids on hippocampal neurons [23, 25, 26]. 
 
Although there are numerous published case reports and reviews on the subject of steroid-
induced neuropsychiatric disorder, the majority of the articles focused in non-cancer 
population. The current literature appears to be limited with regard to evidence of acute and 
prophylactic treatment for steroid-induced disorders especially in cancer populations. 
 
Aims and Objectives 
The aim of this study was to examine the current strength of evidence for treatment and 
prevention of steroid-induced neuropsychiatric effects in cancer. We conducted a 
comprehensive systematic review of the existing literature in both adult and paediatric cancer 
populations to identify all evidence relating to neuropsychiatric effects of steroids, its 
treatment and prevention. 
Methods   
Search Strategy 
We searched the electronic databases including Embase, MEDLINE, PsycINFO and the 
Cochrane Library Database between 21.04.2016 to 21.05.2016 (Appendix 1 shows the 
systematic review protocol). We searched all terms related to steroid, corticosteroid, 
glucocorticoid, prednisolone, dexamethasone and all terms related to neuropsychiatric 
symptoms such as mania, depression, psychosis (Appendix 2 shows the search activity). The 
search was limited to English language publications only. No publication date or age 
restrictions were imposed. A full internet search was conducted using Google and Google 
Scholar, and we also searched the reference lists of relevant papers. 
 
Study selection 
We screened the abstracts of the articles and retrieved the full text of relevant studies that 
fulfilled our inclusion criteria.  Two of us (MFI and CL) selected the studies. We included 
studies in cancer populations only. We included studies such as observational studies, case-
controlled and randomised controlled trials and case series. Only exogenous steroids 
including prednisolone, methylprednisolone, prednisone, dexamethasone, beclomethasone in 
any preparations or mode of administration were included. We excluded studies that met our 
exclusion criteria or had insufficient data. 
 
Study selection and abstraction 
Two authors (MFI and CL) extracted the data independently using a standardized data 
extraction form. The extracted data was compared and in case of disagreements between the 
review authors (MFI and CL), there was a consultation with a third party (EMC). The study 
details that were recorded include general demographic data, sample size, inclusion and 
exclusion criteria, dosage of steroid administered, symptom presentation and interventions 
given. Outcome measures reported by each study were recorded. 
 
Data synthesis 
Studies were grouped according to type of publication (ie case report, case series, other). 
Narrative synthesis was adopted in this study due to the limitation in type of study available. 
Results   
From 4025 potentially relevant citations identified, we retrieved 31 articles of which 6 were 
excluded (figure 1). Two of those excluded were not obtainable [27, 28]; three contained 
insufficient information [29-31] and one related to psychiatric adverse effects of endogenous 
steroid [32]. Nineteen articles [33-51] consisted of case reports; one [52] case series; two [53, 







19 case reports yielded 27 cases in total (table 1). Ages ranged from 2 to 93 years old. 16 
cases were less than 18 year olds. 18 out of 27 were male. Most common cancer diagnosis 
was acute lymphoid leukaemia (n=15), followed by lymphoma (n=4) and myeloma (n=2). 
Dexamethasone was the most commonly prescribed corticosteroid (n=14) followed by 
prednisone (n=6). Prednisone equivalent dose ranged from 16.67mg to 160mg. Fifteen out of 
eighteen cases with documented daily prednisone equivalent doses were over 50mg. 18 cases 
were treated with steroids continuously while 7 were given as pulsed therapy.  
 
Time to onset of neuropsychiatric symptoms ranged from 1 to 30 days from the date of 
commencement of the steroids (Appendix 3). The most common clinical presentations were 
agitation (n=13), insomnia (n=9) and elation (n=8). 1 case tragically culminated in an act of 
homicide [33]. The most common psychiatric outcomes were manic episode (n=16) and 
depressive episode (n=6) (table 2). 15 cases presented with psychotic features including 
paranoid ideation, grandiose ideation, auditory and visual hallucination. Of those 15 cases, 2 
cases were labelled as acute psychotic episodes but the case illustration does not elaborate on 
mood symptoms [33, 38]. 
 
Focusing on the acute intervention for steroid-induced mental disorder, of the 27 cases, 3 
paediatric cases adopted a watchful waiting approach despite remaining on steroids [38]. 
Spontaneous symptom resolution occurred between 3 to 21 days. In one case, intervention 
was in the form of dividing the dose of prednisolone to four times a day [35]; in another, the 
intervention was to switch the steroid from oral to intravenous prednisone [47]. 6 out of 27 
cases discontinued the steroid as part of the acute intervention. 21 cases required 
psychotropic medication for acute intervention. The most common psychotropic medication 
used was risperidone (n=8). 7 of these cases were paediatric. Other psychotropic medications 
used were benzodiazepine only (n=2), promethazine (n=1), antidepressants (n=4) including 
citalopram, imipramine, paroxetine, mianserin and sertraline, and other antipsychotic 
medications including haloperidol (n=4), olanzapine (n=2), aripiprazole (n=1), loxepine 
(n=1) and quetiapine (n=1). Only 1 case used the mood stabiliser lithium carbonate and in 
that case Lithium was used concurrently with antipsychotic medication [50]. 
 
Time to improvement or full resolution of symptoms in the case reports varied. The range for 
improvement of symptoms was between 1 and 21 days. The majority of the cases improved 
within seven days. 18 cases were followed up following re-exposure to steroid. 10 cases had 
a recurrence of mental disorder following the introduction of steroids [37-41, 48, 49]. With 
regard to prophylactic strategies to prevent recurrence, two out of eight cases without 
recurrence adopted a divided steroid strategy [35], three cases continued on antipsychotic and 
mood stabiliser following the first acute presentation [41, 43, 50], and in another case the 
steroid was removed from the chemotherapy regimen [46]. Seven cases adopted a targeted 
approach using psychotropic medication during the course of steroids [37-40, 48, 49]. 
 
Case series 
One case series of 20 patients with steroid-induced mania were treated with sodium 
valproate, five of whom were oncology patients: four had multiple myeloma and one had 
metastatic breast cancer [52]. Patients were recruited from consecutive in-patient referrals to 
a consultation-liaison psychiatry service over a six-year period. Patients who developed 
steroid-induced mania following steroid treatment were included in this study. Sodium 
valproate 500 mg twice daily was administered to all patients and dosage was modified 
according to the valproate level on day three. Patients were followed up daily and Young 
Mania Rating Scale (YMRS) was used daily to monitor the severity of manic symptoms over 
a four-day period. The study shows a rapid improvement of manic symptoms within 48 hours 
with complete resolution in 72 hours. 
 
Other studies 
One study [56] evaluated the incidence of steroid-induced neuropsychiatric episodes in 
adolescents with acute lymphocytic leukaemia (ALL). Of 37 patients included, one third of 
the patients showed mild behavioural disturbances. The most common symptoms were 
anxiety, mood lability and depressive symptoms. 4 adolescents (11%) developed acute 
neuropsychiatric episodes which included severe anxiety, auditory and visual hallucinations 
and impairment in level of consciousness following the reduction of steroids. In the study, 
two patients were treated with antidepressants and the remaining ten patients with symptoms 
of behaviour disturbances were treated with antihistamine (hydroxyzine). 
 
Another study [53] was a retrospective chart review of patients who were referred to a 
psycho-oncology liaison service. The study examined clinical symptoms and levels of 
subjective distress in cancer patients who were treated with steroids. These patients were 
compared to cancer patients who did not receive steroids. The study showed that the steroid 
group was associated with a higher likelihood of presenting with poor concentration, 
psychomotor agitation, elevated mood, irritability and behavioural changes compared to the 
non-steroid group. 
 
One study was a qualitative study evaluating the psychological and psychiatric sequelae of 
steroids in haematological patients [55]. This study provided evidence that emotional 
disturbances were associated with corticosteroid use in patients with haematological cancers. 
Importantly, such disturbances were shown to be independent of the individual's underlying 
emotional health. 
 
Two studies focused on insomnia in oncology patients receiving corticosteroids [54, 57]. One 
retrospective cohort study of patients with recurrent glioma showed that insomnia was 
associated with the use of dexamethasone and anti-epileptic medication [54]. Another study 
was a prospective case-control study which showed that oncology patients who received 
high-dose glucocorticoids as part of their chemotherapy developed insomnia.  The use of 
hypnotics did not significantly improve the quality of their sleep [57].
Discussion 
 
Summary of main results 
In this comprehensive systematic review, we were unable to find any clinical trials relating to 
the acute treatment or prophylaxis of steroid-induced mental disturbances in cancer 
populations. Strategies to treat steroid-induced mental disorders included 
adjusting/discontinuing the steroid preparation, or administering psychotropic medications 
(most commonly antipsychotics) followed by the mood stabilizers such as lithium, sodium 
valproate, benzodiazepines or antidepressants. Two strategies were observed in the case 
reports relating to the prevention of recurrence. The first strategy involved continuation of 
psychotropic medication following the first episode; the second strategy involved a targeted 
approach in which the antipsychotic medication or mood stabiliser was introduced several 
days before, or on the day of, steroid commencement. 
 
In non-cancer populations, only two studies to our knowledge (using the same search 
methodology as per cancer populations) have focused on acute treatment and prophylaxis 
[58, 59] of steroid-induced mental disorders. The first study examined the use of lithium as a 
prophylactic agent in the management of steroid-induced psychiatric side-effects in 27 
patients with multiple sclerosis or retro-bulbar neuritis [58]. None of the patients who were 
administered lithium pre-treatment developed psychiatric side effects whilst on corticosteroid 
therapy. Conversely, 14% of a historical comparison group of 44 patients who were not pre-
treated with lithium became psychiatrically unwell. The study concluded that lithium 
prophylaxis might prevent steroid-induced psychosis and other psychiatric symptoms; 
however, it emphasised that further controlled prospective studies were needed to corroborate 
this finding. The second study, an open-label trial of olanzapine for corticosteroid-induced 
mood symptoms examined the use of olanzapine in 12 outpatients with manic or mixed 
affective symptoms secondary to corticosteroid treatment [59]. Using well-validated rating 
scales, the study showed that olanzapine improved mood in treated subjects and appeared to 
be well tolerated. 
 
Steroid effects in cancer patients 
The exact prevalence of steroid-induced neuropsychiatric effects in cancer patients is 
unknown. The Boston Collaborative Drug Surveillance Programme first reported the 
incidence of steroid-induced psychiatric symptoms in the context of a dose-response 
correlation. Symptoms were noted in 1.3% of 463 patients on prednisolone 40 mg daily, 4.6% 
of 175 patients on 41-80 mg daily, and 18.4% of 38 patients on 80 mg or more daily [15]. 
Since then, studies in cancer patients in particular have shown a 5-10% incidence of 
neuropsychiatric effects in patients on high doses of steroids. Mania and hypomania are the 
most common steroid-induced psychiatric effects in non-cancer patients [18], and there is a 
suggestion that depression can occur in cases of chronic steroid use [55]. 
 
The neuropsychiatric effects of corticosteroids in cancer patients can occur very early on 
during the treatment programs; however, it may not be diagnosed early. This can adversely 
affect patient outcomes by further delaying cancer treatments. Evidence-based guidelines are 
needed on how best to prevent and treat neuropsychiatric steroid effects. However, the 
relative paucity of large-scale, robust, placebo-controlled studies in this field has meant that 
prevention and treatment are largely based on anecdotal evidence.  
 
Although there are numerous published case reports and reviews on the subject of steroid-
induced neuropsychiatric disorder, evidence-based literature related to both prevention and 
treatment of this common problem appears to be limited, particularly in cancer patients. 
Corticosteroids are a key part of chemotherapy for certain types of cancer such as 
haematological cancer. They are also used post-operatively, particularly in head and neck 
cancers. As corticosteroids improve survival rates in cancer patients, their use in cancer 
treatment regimens is paramount. However, it is equally significant that cancer patients are at 
an increased risk of  suicide compared to the cancer-free population [60-62], and 
corticosteroids are shown to increase the risk of suicidality in a small study of a non-cancer 
population [16]. Therefore, the use of steroids in this particular cohort of patients ought to be 
judicious.  
 
The only available evidence to date is based on open-label trials, cohort studies, and case 
series in non-cancer patients. Studies on cancer patients receiving corticosteroid treatment 
regimens have shown that organic mood disorders and delirium are the most frequently 
encountered neuropsychiatric problems [17]. Further studies with cancer patients are needed 
wherein important variables including past psychiatric history, type and site of cancer, 
neurological complications secondary to the malignant process, and general physical health 
are controlled [17]. It is important to add that steroid-related cognitive and mood changes can 
be difficult to diagnose in cancer patients by virtue of the fact that cancer is a multisystem 
disease [32]. Therefore, such changes in the mental state need to have their exact aetiology 
refined and delineated [17]. This issue also extends to the paediatric cancer cohort where 
steroids may form an integral part of treatment for acute lymphoblastic leukaemia and 
Hodgkin’s lymphoma [7]. 
 
Strengths of the study 
To the best of our knowledge, this is the first systematic review of steroid-induced 
neuropsychiatric effects in cancer patients that provides a comprehensive overview of the 
available evidence on prevention and treatment of these effects and the challenges they pose 
to clinicians. Search terms employed to source relevant articles were sensitive, capturing a 
broad range of symptoms and diagnoses relevant to steroid-induced mood disorders. 
 
Limitations of the study 
We excluded non-English articles and therefore may have missed some published cases. 
Further, although our search strategy was comprehensive, it may not have captured all the 
relevant articles available, as some may have utilised terminology other than that employed in 
our literature search.  
 
 
Implications for practice 
Oncology is a discipline in which clinical trials are a key part of everyday practice. There is a 
clear need for clinical trials to enhance the evidence base for the prevention and treatment of 
steroid-induced mental disorders in cancer. These mental disorders are not rare and have a 
significant morbidity. Evidence-based clinical guidelines on the management of steroid-
induced neuropsychiatric effects are lacking both in the existing literature and in practice. 
Such guidelines or recommendations need to be established. To date, no such guidelines or 
recommendations have been established, resulting in heavy reliance on anecdotal evidence 
for the management of these effects.  
 
With respect to options for clinical management, evidence suggests that steroid dose 
reduction or weaning is a favoured strategy in cases of severe mental and behavioural 
disturbance, as is a watchful waiting approach in milder cases. Another treatment strategy is 
to employ evidence-based guidelines for the management of overt hypomania, mania or 
psychosis. This involves treating steroid-induced neuropsychiatric effects with antipsychotic 
medication and a mood stabiliser such as lithium or sodium valproate if no improvement is 
noted. Psychoeducation plays an important role in the management of these effects; patients 
treated with corticosteroids ought to be advised specifically about the possible range of 
neuropsychiatric symptoms secondary to steroid use. 
 
Implications for research 
There is a clear gap in research on the subject of prevention and treatment of steroid-induced 
mental disorders. Additional randomised controlled trials are needed to examine preventive 
strategies, such as the prophylactic use of psychotropic medication in patients who 
experience steroid-induced mental disorders. It would be useful to assess the impact of 
steroid-induced mood disorders and potential treatments in cancer populations in particular. 
This involves a number of questions for future research, such as if steroid-induced mental 
disorders delay cancer interventions or affect compliance with cancer treatment regimens, if 
cancer treatments in oncology patients with steroid-induced neuropsychiatric effects 
adversely affect health outcomes, and if patient survival is affected as a consequence of these.  
 
Conclusion  
The range of neuropsychiatric side effects of corticosteroid treatment is broad, varying from 
mild mood changes to mania and psychosis. There is a paucity of robust clinical research on 
the prevention and treatment of these effects, particularly in relation to cancer patients. This 
study has demonstrated that various strategies can be employed to treat mental and 
behavioural disturbances secondary to the administration of steroids, as well as prevent their 
recurrence, both in cancer and non-cancer patients. However, it also emphasises the limited 
evidence for these treatment and prevention strategies, which are needed to guide clinicians 
in the prevention and treatment of steroid-induced psychiatric disorders. This research gap 
should be addressed as a priority through multi-centre clinical trials. 
Future Perspectives 
There is a clear gap in research on the subject of prevention and treatment of steroid-induced 
mental disorders. We speculate that at the initial stage, researchers will focus on the impact of 
steroid-induced mood disorders to address a number of questions, such as if steroid-induced 
mental disorders delay cancer interventions or affect compliance with cancer treatment 
regimens, which may affect morbidity and mortality. 
 
In the future, more research will be conducted to assess the predictive factors and the risk of 
developing steroid-induced mental disorders following corticosteroid treatment. Furthermore, 
this will lead to a development of screening tools to stratify the risk and guide clinicians with 
regard to treatment and  prophylaxis. 
We also envision that in the future there will exist an established guideline for the acute 
treatment of, and guidelines in the management of the recurrence of, steroid-induced mental 
disorders. Antipsychotic medication and mood stabilisers will most likely provide the 






• Corticosteroids are central to many cancer treatment regimens. However, 
corticosteroids can lead to serious neuropsychiatric adverse effects including mania, 
psychosis, severe depression and deslirium. 
• Although there are numerous published case reports and reviews on the subject of 
steroid-induced neuropsychiatric disorder, the majority of the articles focused on non-
cancer populations. 
• In this systematic review, we were unable to find any clinical trials relating to the 
acute treatment or prophylaxis of steroid-induced mental disturbances in cancer 
populations. The results were limited to case reports and case series. 
• Strategies to treat steroid-induced mental disorders included adjusting/discontinuing 
the steroid preparation, or administering psychotropic medications (most commonly 
antipsychotics) followed by mood stabilizers such as lithium, sodium valproate, 
benzodiazepines or antidepressants. 
• Two strategies were observed in the case reports relating to the prevention of 
recurrence. The first strategy involved continuous use of psychotropic medication 
following the first episode; the second strategy involved a targeted approach. 
• There is a clear gap in research on the subject of prevention and treatment of steroid-
induced mental disorders. Additional randomised controlled trials are needed to 
examine treatment strategies in the acute and prophylactic treatment of steroid-
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